Greg Brown

Dr. Greg Brown is a highly accomplished professional with a diverse background in biotechnology, healthcare, and finance.

Currently serving as the Chief Executive Officer of Memgen, a leading biotechnology company in Houston, TX, Dr. Brown brings a wealth of experience and expertise to the industry.

With a strong educational foundation that includes an M.D. from SUNY Upstate Medical Center, an MBA from Harvard Business School, and an A.B. from Yale University, Dr. Brown has pursued a career that spans various sectors.

Prior to his role at Memgen, Dr. Brown co-founded HealthCare Royalty Partners and held the position of Vice Chairman, demonstrating his entrepreneurial spirit and leadership capabilities.

His professional journey also includes significant roles such as Partner at Paul Capital Partners, Managing Director at Adams, Harkness & Hill, and Vice President at Vector Securities International Inc., where he honed his skills in investment banking and healthcare.

Dr. Brown's expertise extends to areas such as transplantation immunology, thoracic and vascular surgery, healthcare systems, and product evaluation, making him a well-rounded professional in the field.

His contributions to the industry are evident through his involvement in sourcing and closing substantial royalty financings, totaling over $1 billion, highlighting his financial acumen and strategic foresight.

Dr. Brown's commitment to advancing healthcare is further underscored by his board positions at notable organizations like Aquestive Therapeutics, Inc., Caladrius Biosciences, Inc., Faron Pharmaceuticals, Oy, FAST BioMedical, Inc., and Memgen Bio.

Throughout his career, Dr. Brown has leveraged his multifaceted background to drive innovation, facilitate investment opportunities, and contribute to the growth of the biotechnology and healthcare sectors.

His strategic mindset, combined with his extensive experience in both medical and business domains, positions Dr. Brown as a distinguished leader in the industry.